Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

• Status: Completed
• Trial end date: 2020-02-29
• Target enrollment: 0
• Participant gender: Female

Summary

lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ganin Fertility Center
• Treatments: Bromocriptine; Fludrocortisone

Criteria

Inclusion Criteria: patients undergoing ICSI who were considered at risk of developing OHSS:

• polycystic ovaries and/or previous history of OHSS, AMH > 40 pmol/L but patients were finally included in the study if serum E2 levels reached >3000 pg/ml on day of hCG trigger or at any stage of folliculometry

• age: 18-40

Exclusion Criteria:

• retrieval of less than 20 oocytes

• age less than 18 or above 40